Literature DB >> 16404635

Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.

Timothy C Cheng1, Gerald Manorek, Goli Samimi, Xinjian Lin, Charles C Berry, Stephen B Howell.   

Abstract

The goal of this study was to identify genes consistently differentially expressed in multiple pairs of isogenic cisplatin (DDP)-sensitive and resistant human ovarian carcinoma cell lines using microarray-based expression profiling. Expression profiling was carried out on six pairs of ovarian carcinoma cells lines growing under identical conditions; each cell expression profile was independently replicated six times. No genes were differentially expressed in all six pairs of cells or even in even in any five of the six pairs. Eighteen genes and 1 EST were upregulated, and four genes and 1 EST were downregulated, in at least four cell pairs. Of these, only metallothionein 2A has previously been implicated in DDP resistance. Among the genes identified on the basis of six replicates, an average of 24.8% would have been missed if only five replicates had been performed, and 38.3% would have been missed with only four replicates. The genes did not identify a dominant biochemical pathway or ontology category as being linked to DDP resistance; however, hierarchical clustering provided evidence for two classes DDP-resistant phenotypes within which there are additional cell pair-specific alterations. Many of the genes identified in this study play important roles in cell surface interactions and trafficking pathways not previously linked to DDP resistance. The genes discovered by this extensively replicated analysis are candidates for prediction of DDP responsiveness in ovarian cancer patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16404635     DOI: 10.1007/s00280-005-0171-8

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.

Authors:  Ding-Wu Shen; Jichun Ma; Mitsunori Okabe; Guofeng Zhang; Di Xia; Michael M Gottesman
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

Authors:  M D Bacolod; S M Lin; S P Johnson; N S Bullock; M Colvin; D D Bigner; H S Friedman
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

3.  Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency.

Authors:  Xiaoqin Yuan; Xinjian Lin; Gerald Manorek; Stephen B Howell
Journal:  BMC Cancer       Date:  2011-02-08       Impact factor: 4.430

4.  Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.

Authors:  Xiying Shang; Xinjian Lin; Edwin Alvarez; Gerald Manorek; Stephen B Howell
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

5.  Synergy between PPARgamma ligands and platinum-based drugs in cancer.

Authors:  Geoffrey D Girnun; Elnaz Naseri; Scott B Vafai; Lishu Qu; Jeffrey D Szwaya; Roderick Bronson; John A Alberta; Bruce M Spiegelman
Journal:  Cancer Cell       Date:  2007-05       Impact factor: 31.743

6.  MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.

Authors:  Lirong Ren; Lan Xiao; Jianli Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-12

7.  EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.

Authors:  Alexandria M Haslehurst; Madhuri Koti; Moyez Dharsee; Paulo Nuin; Ken Evans; Joseph Geraci; Timothy Childs; Jian Chen; Jieran Li; Johanne Weberpals; Scott Davey; Jeremy Squire; Paul C Park; Harriet Feilotter
Journal:  BMC Cancer       Date:  2012-03-19       Impact factor: 4.430

8.  Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4.

Authors:  Xinjian Lin; Xiying Shang; Gerald Manorek; Stephen B Howell
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

9.  HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

Authors:  Euan A Stronach; Albandri Alfraidi; Nona Rama; Christoph Datler; James B Studd; Roshan Agarwal; Tankut G Guney; Charlie Gourley; Bryan T Hennessy; Gordon B Mills; Antonello Mai; Robert Brown; Roberto Dina; Hani Gabra
Journal:  Cancer Res       Date:  2011-05-13       Impact factor: 12.701

10.  Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel.

Authors:  Stephen R Armstrong; Rashmi Narendrula; Baoqing Guo; Amadeo M Parissenti; Katherine L McCallum; Stephanie Cull; Carita Lannér
Journal:  J Ovarian Res       Date:  2012-11-30       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.